

## EFFICACY OF ORAL AND INTRAMUSCULAR VITAMIN B<sub>12</sub> IN EARLY RESPONSE AND PREFERENCES OF PATIENTS

Shahzad Ali Jiskani,<sup>2</sup> Muhammad Muqeem Mangi,<sup>3</sup> Rehana Guddi Siddiqui,<sup>4</sup> Anam Shaikh,<sup>5</sup> Halar Rahim,<sup>6\*</sup> Ali Akbar Pirzado

<sup>1</sup>Assistant Professor, Department of Pathology, Chandka Medical College @ SMBBMU, Larkana

<sup>2</sup>Associate Professor, Department of Physiology, Suleman Roshan Medical College, Tando Adam

<sup>3</sup>Senior Lecturer, Department of Community Medicine & Public Health, Ghulam Muhammad Mahar Medical College, Sukkur

<sup>4</sup>Assistant Professor, Department of Pathology, Indus Medical College, The University of Modern Sciences, Tando Muhammad Khan

<sup>5</sup>Postgraduate Resident, Department of Medicine, Jinnah Postgraduate Medical Center, Karachi

<sup>6\*</sup>Statistical Officer Department of Community Medicine & Public Health, Chandka Medical College @ SMBBMU, Larkana

**Corresponding Author:** <sup>6\*</sup> Ali Akbar Pirzado (apirzado@smbbmu.edu.pk)

### ABSTRACT

**BACKGROUND:** Deficiency of vitamin B<sub>12</sub> can be managed by oral substitution or intramuscular injection of vitamin B<sub>12</sub>. When different administration routes are present, the preference of patients should also be considered while treatment selection.

**OBJECTIVE:** The main objective of our study was to assess the preferences of patients towards intramuscular injection or oral treatment of vitamin B<sub>12</sub> supplementation, and to confirm the efficacy of both treatment options in patients.

**METHODOLOGY:** This was a prospective clinical trial, conducted at tertiary care hospital for a period of one year (June 2020 to May 2021). A total of 42 patients were selected for study. Patients were randomly and equally allocated to oral (21 patients) or intramuscular treatment groups (21 patients). In Group A, patients were given oral tablets of 1000µg cyanocobalamin, while in Group B, 1000µg hydroxocobalamin injections were given to patients. Samples of whole blood were extracted before starting of treatment, followed by 1, 2 and 4 weeks of treatment, and were analyzed for serum vitamin B<sub>12</sub> levels. Before and after treatment, the patients were asked to fill questionnaire regarding preference of treatment options. SPSS 24.0. was used for analysis. A p-value of <0.05 was considered as statistically significant.

**RESULTS:** Among all patients, the mean age was found as 46.3±3 years with majority were including the females (63.3%). In Group A, serum vitamin B<sub>12</sub> levels were 155 pmol/L (range 144-181) and Group B, it was 161 pmol/L (range 149-169). After 1 month of therapy, the level

of serum vitamin B<sub>12</sub> level was increased significantly in Group A (368; range 295-419) and Group B (2881 (range 1297-4418)). Before starting of treatment, most of the preference was given to oral route of administration. Eight patients changed their opinion after therapy.

**CONCLUSION:** There was significant difference in levels of vitamin B<sub>12</sub> in both oral and intramuscular treatment groups. Due to obvious effect in response to treatment, the opinion of patients to select the routes of administration was also changed.

**Keywords:** Vitamin B<sub>12</sub>, Oral therapy, Intramuscular therapy, Preference, Cyanocobalamin.

## INTRODUCTION

Vitamin B<sub>12</sub> deficiency is common clinical entity, widely presents in combination with other conditions or isolated. The overall prevalence in adults is 8-16%, while in elderly, it is 5-40%.<sup>(1-2)</sup> Though the actual prevalence in global population is still not known, although it seems to increase with age, mostly due absorption impairment.<sup>(3-4)</sup>

Various causes may lead to deficiency of vitamin B<sub>12</sub> including nutritional/dietary, malabsorption, and other causes related to gastrointestinal tract.<sup>(5-6)</sup> Pernicious anemia is usually presented as hematological clinical features and is related to intrinsic factors antibodies and/or gastric parietal cells antibodies, though it contributes a minor amount of cause of vitamin B<sub>12</sub> deficiency.<sup>(7)</sup> Additionally, defect in mechanisms of transport because of genetic factors are also among minor causes.<sup>(8)</sup> Therapy with metformin and acid-lowering agents may take part in etiology of vitamin B<sub>12</sub> deficiency.

There are various clinical presentations associated with deficiency of vitamin B<sub>12</sub>. In addition to non-specific symptoms including loss of appetite and tiredness, neurological diseases (i.e., ataxia, polyneuropathy), hematological diseases (i.e., megaloblastic anemia), and psychiatric problems (i.e., depression) may also be seen.<sup>(8, 12)</sup> Cardiovascular problems in association with hyperhomocysteinemia may also present.<sup>(13-16)</sup> As deficiency of vitamin B<sub>12</sub> is not an irreversible cause of demyelinating diseases and failure of bone marrow, early detection and adequate treatment are essential.<sup>(12)</sup>

Various causes make indications for treatment by vitamin B<sub>12</sub> supplementation, including dietary deficiency, pernicious anemia, and gastrectomy).<sup>(12)</sup> In pregnancy females on Mediterranean diet, patients with nitrous oxide exposure and gastric surgery, and patients on pure vegetarian diet may be treated prophylactically.<sup>(17)</sup> Although, official threshold for starting of treatment is not established yet. On laboratory methods, the deficiency of vitamin B<sub>12</sub> is defined as borderline to subnormal level of vitamin B<sub>12</sub> in serum. Holotranscobalamin is a bioactive state of vitamin B<sub>12</sub> is considered as more sensitive and specific marker of vitamin B<sub>12</sub> deficiency.<sup>(18-20)</sup> Functional deficiency of vitamin B<sub>12</sub> is recognized by high homocysteine and/or methylmalonic acid. Functional analysis is considered when there is high suspicion of vitamin B<sub>12</sub> deficiency, moderately low levels of vitamin B<sub>12</sub>, in patients having unexplained neurological problems or macrocytosis, or when deficiency of vitamin B<sub>12</sub> is highly possible as

manageable cause of dementia in patients. <sup>(17)</sup> Subclinical deficiency of vitamin B<sub>12</sub> is present in 10-25% of aged population. <sup>(17)</sup>

The management of vitamin B<sub>12</sub> deficiency include vitamin B<sub>12</sub> supplementation by either oral or intramuscular route of administration. In patients with severe deficiency of vitamin B<sub>12</sub>, 1000µg injection should be given several times in a week for 1-2 weeks, followed by weekly and monthly injections. <sup>(12, 17)</sup> In patients with dietary deficiency of mild malabsorption, initial high dose oral treatment can be given. <sup>(12)</sup> As the absorption of vitamin B<sub>12</sub> is not predictable in severe cases or when frequent monitoring is required, initial parenteral route should be used, followed by oral route after normalization of serum vitamin B<sub>12</sub> levels. <sup>(17)</sup>

In western countries, supplementation of vitamin B<sub>12</sub> is mainly given as intramuscular injections. <sup>(21)</sup> Though, evidence of good effectiveness of oral supplementation is available, there is no high-dose oral vitamin B<sub>12</sub> monopreparation available. <sup>(22-24)</sup> Even in the presence of gastrointestinal diseases, oral vitamin B<sub>12</sub> treatment shows satisfactory response. A study revealed that deficiency of vitamin B<sub>12</sub> can be inverted in patients undergone gastrectomy. <sup>(25)</sup> Although there is limited data available for effectiveness of high oral dose of vitamin B<sub>12</sub> supplementation in comparison to intramuscular route. <sup>(26)</sup>

As compared to intramuscular route, oral vitamin B<sub>12</sub> may show cost-effectiveness and patient acceptance. <sup>(27)</sup> Preferences of patients in treatment decision should also be considered. <sup>(28)</sup> Additionally, a better sense of patient values and preferences to make choice is basic for achievement of shared making of decision and eventually enhancing the adherence.

This study aimed to evaluate preference of vitamin B<sub>12</sub> treatment by intramuscular or oral route, and to validate the effectiveness of early biomarker for monitoring of oral treatment with vitamin B<sub>12</sub> supplementation.

## PATIENTS AND METHODS

This was a randomized controlled trial, conducted at tertiary care hospital. The study was conducted for a period of one year (June 2020 to May 2021).

### Participants

Patients were randomly and equally allocated to oral (21 patients) or intramuscular treatment groups (21 patients). Patients with serum vitamin B<sub>12</sub> concentration of <200 pmol/L, age ≥18 years and who gave consent were included in this study. Patients taking vitamin supplementation including vitamin B<sub>12</sub>, or who has history of dementia, known defects of hereditary transcobalamin transportation were excluded from the study.

## Interventions

In patients with oral treatment group, one tablet (1000 $\mu$ g) cyanocobalamin was instructed daily for 28 consecutive days. In patients with intramuscular treatment group, conventional treatment with injection of 1000 $\mu$ g hydroxocobalamin weekly was instructed.

## Outcomes of Adherence

The adherence rates were calculated as (i) adherence with count of pills, which is explained as percentage of days with performed pill intakes divided by days of prescribed pill intakes, and (ii) irregularities of dosing, which is explained as percentage of days with  $\geq 2$  events of dosing.

## Assessment of Biomarkers

Venous whole blood samples were extracted prior to initial administration (V0), followed by after 1 (V7), 2 (V14), and four weeks of treatment (V28). The blood samples were transported in two collection tubes. For hematological analysis, blood samples were collected in EDTA-containing tube and were analyzed using automated hematology analyzer. The other samples were collected in clot activator tubes for analysis of folate and vitamin B<sub>12</sub> levels using automated immunoassay analyzer.

## Preferences of Patients

The preferences of patients were determined before randomization (V0) and after four weeks of treatment (V28). Patients were asked to choose oral, injectable or no preference by the help of questionnaire. The questionnaire contained various items including disgust, pain, effectiveness, side effects, difficulties, inconveniences, costs, time consumption, and nonadherence to scheduled treatment.

## Statistical Analysis

Quantitative values are shown as mean, standard deviation, median and percentages. To compare the numerical variables between two groups, Mann-Whitney test was used and for three groups, Kruskal-Wallis test was used. A p-value of  $<0.05$  was considered as statistically significant.

## RESULTS

A total of 42 patients were selected for the study and were divided into oral group (n=21), and intramuscular group (n=21). The baseline characteristics of both groups are summarized table 1. Comparison of vitamin B<sub>12</sub> levels was done between both groups. At day 0 visit, initial baseline value was approximately equal with no significant changes. Though the levels were remarkably high in intramuscular group at consecutive day 7, 14, and 28 (p<0.001) (Table 2). Preference of patients was also analyzed. Majority of patients preferred oral route of administration over intramuscular due to various factors (Table 3). Majority of patients were

having concern regarding pain, disgust, side effects, inconvenience, and time consumption. Few patients changed their preference after therapy.

*Table 1: Baseline Characteristics of Patients (n=42)*

Parameter	Group O-Oral (n=21)	Group I-IM (n=21)	p-value
Age (years)	45.23 ± 12.44	47.32 ± 13.12	0.32
Body mass index (kg/m <sup>2</sup> )	28.18 ± 6.56	27.97 ± 7.43	0.41
Vitamin B <sub>12</sub> levels (pmol/L)	141 ± 23.41	144 ± 20.39	0.48

*Table 2: Comparison of Levels of Vitamin B12 (pmol/L) at Consecutive Visit Days (n=42)*

Visit Day	Group O-Oral (n=21) (pmol/L)	Group I-IM (n=21) (pmol/L)	p-value
Day 0	155	161	0.48
Day 7	310	1103	<0.001
Day 14	331	1788	<0.001
Day 28	368	2881	<0.001

*Table 3: Preference of Patients and Associated Factors in Choosing Treatment (n=42)*

Parameter		Prefers Oral (n=24)	Prefers IM (n=8)	No preference (n=12)	p-value
Pain	Syringes	5.1 ± 1.88	3.3 ± 1.4	2.4 ± 1.1	0.001
	Tablets	1.1 ± 0.01	2.0 ± 2.1	1.0 ± 0.2	0.112
Repulsion	Syringes	5.8 ± 2.2	3.2 ± 2.1	3.1 ± 2.1	0.005
	Tablets	3.2 ± 1.6	4.7 ± 2.3	2.4 ± 1.2	0.034
Side effects	Syringes	4.4 ± 2.1	2.3 ± 1.5	2.4 ± 1.4	0.011

	Tablets	2.1 ± 1.1	2.6 ± 2.1	2.3 ± 1.2	0.054
Effectiveness of Treatment	Syringes	8.1 ± 1.3	8.9 ± 1.0	8.6 ± 1.4	0.65
	Tablets	7.3 ± 2.4	6.7 ± 2.1	7.8 ± 1.4	0.44
Inconvenience	Syringes	6.6 ± 1.6	2.5 ± 1.3	2.5 ± 1.1	<0.001
	Tablets	2.6 ± 1.3	4.9 ± 2.2	2.3 ± 1.8	0.019
Difficulties	Syringes	4.8 ± 2.6	1.9 ± 1.6	1.5 ± 0.9	0.002
	Tablets	1.8 ± 1.7	1.8 ± 1.3	1.2 ± 0.5	0.854
Consumption Time	Syringes	7.2 ± 2.4	4.3 ± 2.5	2.5 ± 1.1	<0.001
	Tablets	1.3 ± 0.3	2.5 ± 1.0	1.4 ± 1.0	0.002
Cost Effectiveness	Syringes	4.7 ± 2.3	4.1 ± 2.8	3.7 ± 2.6	0.601
	Tablets	2.9 ± 1.6	2.6 ± 1.6	2.3 ± 2.5	0.552
Non-adherence to treatment	Syringes	3.5 ± 2.4	3.9 ± 2.6	2.9 ± 2.9	0.411
	Tablets	2.5 ± 2.5	4.6 ± 1.9	2.8 ± 2.3	0.02

## DISCUSSION

In current study, the level of vitamin B<sub>12</sub> was increased after 28 days of oral and/or intramuscular high – dose vitamin B<sub>12</sub> therapy. Other studies also support these findings, in which two trials assessed effect of high – dose oral vitamin B<sub>12</sub> therapy in comparison of placebo<sup>(24, 29-30)</sup>, while three trails compared oral vs intramuscular vitamin B<sub>12</sub> therapy.<sup>(22-23, 31)</sup>

In disparity of other studies, we detected increased response after intramuscular administration, hence the theory of non-inferiority of oral administration in comparison of intramuscular administration should not be accepted. The reason of high response may be due to use of hydroxocobalamin, which is intermediate form that is widely accessible to cells in contrast to other forms of cobalamin.<sup>(32)</sup> In pediatric patients with deficiency of vitamin B<sub>12</sub>, one intramuscular injection of hydroxocobalamin (400µg) improved the motor function and repletion of cobalamin.<sup>(33)</sup> Furthermore, retention of hydroxocobalamin is longer in plasma in comparison to other cyanocobalamin doses, allowing the less frequency of dosing. Although, due to low stability of hydroxocobalamin, it is less suitable for oral administration, therefore, cyanocobalamin is used commonly for oral administration as it is inexpensive and more stable.<sup>(34)</sup> Sustainability of the biomarker response after intramuscular hydroxocobalamins has not understood completely. In a study, among 8 patients with vitamin B<sub>12</sub> deficiency having levels <80pg/mL, vitamin B<sub>12</sub> levels were increased to 300-1100 pg/mL after 10 days of high – dose

intramuscular hydroxocobalamin. <sup>(35)</sup> In our study, wide variation response of vitamin B<sub>12</sub> was seen within intramuscular group, which relates to various individual variations in pharmacokinetics of hydroxocobalamin mentioned by others. <sup>(36-37)</sup>

There are no studies available for increased levels of vitamin B<sub>12</sub> with daily oral vitamin B<sub>12</sub> administration over longer period of treatment same as that observed after intramuscular administration. In a study, high-dose oral vitamin B<sub>12</sub> administration for 3 months increased the vitamin B<sub>12</sub> levels in patients having initial low levels as compared to our study in which similar response was seen in 28 days. <sup>(30)</sup> Continuation of the therapy did not change the levels of vitamin B<sub>12</sub> significantly up to 6 months. <sup>(30)</sup> One study demonstrated a highland in serum vitamin B<sub>12</sub> levels (mean = 1164 pg/mL) after treatment of 3 months with high – dose hydroxocobalamin and consequent treatment up to 18 months with high – dose oral cyanocobalamin. <sup>(38)</sup> These findings explained that continuous treatment with high – dose oral vitamin B<sub>12</sub> reaches serum vitamin B<sub>12</sub> saturation after treatment of 3 months. In current study, four patients did not reach normal vitamin B<sub>12</sub> levels after oral administration. Although, two of those patients had normal levels at day 14 visit, followed by decline afterwards. Keeping rational reasons aside e.g., compliance etc., these results suggest that saturation time of vitamin B<sub>12</sub> may vary among patients. Remaining two patients responded slowly, suggestive of underlying cause of vitamin B<sub>12</sub> deficiency. Additionally, active part of vitamin B<sub>12</sub> reached the normal value at visit day 28. One of the reasons of non-responsiveness in oral group could be pernicious anemia. Although, as all patients showed some response or reached physiological rationale for slow response, this hypothesis was less likely to be true.

After treatment with intramuscular hydroxocobalamin, the supratherapeutic levels were observed, which may not be possible with oral administration. Furthermore, normalization of all parameters was seen more in intramuscular group as compared to oral group. Although, in oral group, incomplete response was limited to vitamin B<sub>12</sub>. Therefore, the advantage of such increased response to intramuscular therapy seems limited to practice use in the state of decreased administrations e.g., long intervals in treatment, and when symptomatic patient requiring quick normalization of markers. Further studies should be performed for assessment of effects of various cobalamin forms on biomarkers and clinical outcomes. As so, obtained variations between different forms of cobalamin should be included in vitamin B<sub>12</sub> treatment guidelines.

As traditionally expected, the preference of patients was oral administration, both before and after completion of treatment. Other studies were also in line with our findings in terms of oral treatment preferences. <sup>(38-39)</sup> In one study, 83% patients preferred oral administration in comparison to intramuscular. <sup>(38)</sup> In other study, the patients were being treated by intramuscular route, but they were willing to switch to oral treatment. Major factors to switch from intramuscular to oral route was high cost, disadvantage of injections, and convenience with oral therapy. <sup>(39)</sup> In our study, we observed inconvenience and time consumption of intramuscular treatment as compared to oral administration.

There was slight variation in patient preference after getting oral treatment, whereas variation occurred only in favor of oral administration. This suggests that patients value the administration route more after experiencing treatment with oral route in firsthand. After receiving intramuscular treatment, the change in preference was observed in few patients in different directions. In terms of increased intramuscular treatment response, the needed frequency of injections in clinical scenario may be decreased in mild deficiency of vitamin B<sub>12</sub>. Further studies with validated methods are required to achieve insight preference of patients.

## CONCLUSION

Variations in level of vitamin B<sub>12</sub> were increased than expected levels. Hence, theory of non-inferiority oral therapy should not be used. Effects of biomarker at midterm and preferences of patients should be considered while choosing the treatment plan of patients. Initial preferences of oral and/or intramuscular route may vary over time and explains frequent re-assessment of patient preferences. However, many patients preferred oral administration prior to and after therapy. Additional studies may help for evaluation regarding route of administration.

## REFERENCES

- 1. Awasthi S, Kumar D, Singh S, Dixit S, Agarwal G, Mahdi AA. Prevalence of specific micronutrient deficiencies in urban school going children of India aged between 6 and 16 years: study protocol for a multicentric cross-sectional study. *BMJ Open.* 2021;11(12): e046783.**
- 2. Sahni P. The Screening and Treatment of Vitamin B12 Deficiency. *IHRJ.* 2021;5(4):RV1-RV5.**
3. Clements M, Ward M, Hughes CF, Hoey L, Johnston A, Molloy AM, et al. Impact of food-bound malabsorption on vitamin B12 status in older adults from the TUDA Ageing Cohort Study: preliminary findings. *Proceedings of the Nutrition Society.* Cambridge University Press; 2020;79(OCE2): E587.
- 4. Vincenti A, Bertuzzo L, Limitone A, D'Antona D, Cena H. Perspective: Practical Approach to Preventing Subclinical B12 Deficiency in Elderly Population. *Nutrients.* 2021; 13:1913.**
5. Azzini E, Raguzzini A, Polito A. A Brief Review on Vitamin B<sub>12</sub> Deficiency Looking at Some Case Study Reports in Adults. *Int J Mol Sci.* 2021;22(18):9694.
6. Naik S, Mahalle N, Bhide V. Identification of vitamin B12 deficiency in vegetarian Indians. *British Journal of Nutrition.* Cambridge University Press; 2018;119(6):629–35.
7. Azimi S, Faramarzi E, Sarbakhsh P, Ostadrahimi A, Somi MH, Ghayour M. Folate and vitamin B12 status and their relation to hematological indices in healthy adults of Iranians: Azar cohort study. *Nutrition and Health.* 2019;25(1):29-36.



8. Sobczynska-Malefora A, Delvin E, McCaddon A, Ahmadi KR, Harrington DJ. **Vitamin B<sub>12</sub> status in health and disease: a critical review. Diagnosis of deficiency and insufficiency – clinical and laboratory pitfalls. Critical Reviews in Clinical Laboratory Sciences. 2021;58(6):399-429.**
9. Miller JW. Proton Pump Inhibitors, H<sub>2</sub>-Receptor Antagonists, Metformin, and Vitamin B-12 Deficiency: Clinical Implications. *Adv Nutr.* 2018;9(4):511S-518S..
10. Cagle S, Song S. **Does long-term use of proton pump inhibitors cause B12 deficiency? Evidence-Based Practice. 2019;22(5):23-24.**
11. Kim J, Ahn CW, Fang S, Lee HS, Park JK. **Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes. Medicine. 2019;98(46): e17918.**
12. Singh J, Dinkar A, Gupta P, Virendra A. **Vitamin B12 deficiency in northern India tertiary care: Prevalence, risk factors and clinical characteristics. Journal of Family Medicine and Primary Care. 2022;11(6):2381-2388.**
13. Cianciolo G, De-Pascalis A, Di-Lullo L, Ronco C, Zannini C, La-Manna G. **Folic Acid and Homocysteine in Chronic Kidney Disease and Cardiovascular Disease Progression: Which Comes First? Cardiorenal Med. 2017; 7(4):255-266.**
14. Grant R, Pawlak R, Vos P, et al. Cardiovascular Disease Risk Factors Profile Among Australian Vegetarian and Nonvegetarian Teenagers. *American Journal of Lifestyle Medicine.* 2021;15(3):313-321.
15. Alawneh I, Saymeh A, Daragham M, Jabri D, Yaseen L. Role of plasma homocysteine levels and other associated factors with coronary artery disease among Palestinian patients in North Palestine: a case control study. *Pan African Medical Journal.* 2022; 42:180.
16. Chen S, Honda T, Ohara T, Hata J, Hirakawa Y, Yoshida D et al. Serum homocysteine and risk of dementia in Japan *Journal of Neurology, Neurosurgery & Psychiatry* 2020;91:540-546.
17. Azzini E, Raguzzini A, Polito A. A Brief Review on Vitamin B<sub>12</sub> Deficiency Looking at Some Case Study Reports in Adults. *International Journal of Molecular Sciences.* 2021; 22(18):9694.
18. Metaxas C, Zurwerra C, Rudofsky G, Hersberger KE, Walter PN. **Impact of type 2 Diabetes and Metformin use on Vitamin B12 Associated Biomarkers – an Observational Study. Exp Clin Endocrinol Diabetes. 2018; 126:394-400.**
19. Hughes CF, McNulty H. Assessing biomarker status of vitamin B12 in the laboratory: no simple solution. *Annals of Clinical Biochemistry.* 2018;55(2):188-189.

20. Allen LH, Miller JW, de Groot L, Rosenberg IH, Smith AD, Refsum H, Raiten DJ. Biomarkers of Nutrition for Development (BOND): Vitamin B-12 Review. *J Nutr.* 2018;148(suppl\_4):1995S-2027S.
21. Ashok T, Puttam H, Tarnate VCA, Jhaveri S, Avanthika C, Trevino AT et al. Role of Vitamin B12 and Folate in Metabolic Syndrome. *Cereus.* 2021;13(10): e18521.
22. Kuzminski AM, Del Giacco EJ, Allen RH, Stabler SP, Lindenbaum J. Effective treatment of cobalamin deficiency with oral cobalamin. *Blood.*1998;92(4):1191–8.
23. Bolaman Z, Kadikoylu G, Yukselen V, Yavasoglu I, Barutca S, Senturk T.Oral versus intramuscular cobalamin treatment in megaloblastic anemia: asingle-center, prospective, randomized, open-label study. *Clin Ther.*2003;25(12):3124–34.
24. Favrat B, Vaucher P, Herzig L, Burnand B, Ali G, Boulat O, et al. Oral vitamin B12 for patients suspected of subtle cobalamin deficiency: a multicentre pragmatic randomised controlled trial. *BMC Fam Pract.* 2011;12(1):2.
25. Adachi S, Kawamoto T, Otsuka M, Todoroki T, Fukao K. Enteral vitaminB12 supplements reverse postgastrectomy B12 deficiency. *Ann Surg.*2000;232(2):199–201.
26. Wang H, Li L, Qin LL, Song Y, Vidal-Alaball J, Liu TH. Oral vitamin B<sub>12</sub> versus intramuscular vitamin B<sub>12</sub> for vitamin B<sub>12</sub> deficiency. *Cochrane Database Syst Rev.* 2018;3(3):CD004655.
27. Schijns W, Homan J, Van-der-Meer L, Janssen IM, Van-Laarhoven CJ, Berends FJ et al. Efficacy of oral compared with intramuscular vitamin B12 supplementation after Roux-en-Y gastric bypass: a randomized controlled trial. *Am J Clin Nutr.* 2018; 108:6-12.
28. Mbewe N, Vinikoor MJ, Fwoloshi S, Mwitumwa M, Lakhi S, Sivile S et al. Advanced HIV disease management practices within inpatient medicine units at a referral hospital in Zambia: a retrospective chart review. *AIDS Res Ther.* 2022; 19:10.
29. Arnet I, Walter PN, Hersberger KE. Polymedication Electronic MonitoringSystem (POEMS) - a new technology for measuring adherence. *Front Pharmacol.* 2013; 4:26.
30. Eussen SJ, de Groot LC, Joosten LW, Bloo RJ, Clarke R, Ueland PM, et al.Effect of oral vitamin B-12 with or without folic acid on cognitive functionin older people with mild vitamin B-12 deficiency: a randomized, placebocontrolled trial. *Am J Clin Nutr.* 2006;84(2):361–70.
31. Castelli MC, Friedman K, Sherry J, Brazzillo K, Genoble L, Bhargava P, etal. Comparing the efficacy and tolerability of a new daily oral vitamin B12formulation and intermittent intramuscular vitamin B12 in normalizing lowcobalamin levels: a randomized, open-label, parallel-group study. *Clin Ther.*2011;33(3):358–371.e2.

32. Gebremicael G, Alemayehu M, Sileshi M, Geto Z, Gebreegziabxier A, Tefera H et al. The serum concentration of vitamin B12 as a biomarker of therapeutic response in tuberculosis patients with and without human immunodeficiency virus (HIV) infection. *Int J Gen Med.* 2019; 12:353-361.
33. Strand TA, Ulak M, Hysing M, Ranjitkar S, Kvestad I, Shrestha M et al. Effects of Vitamin B<sub>12</sub> supplementation on neurodevelopment and growth in Nepalese Infants: A randomized controlled trial. *PLoS Med.* 2020;17(12): e1003430.
34. Greibe E, Kornerup LS, Juul CB, Fedosov SN, Heegaard CW, Nexø E. The tissue profile of metabolically active coenzyme of vitamin B<sub>12</sub> differs from vitamin B<sub>12</sub> – depleted rats treated with hydroxo-B<sub>12</sub> or cyano-B<sub>12</sub>. *British Journal of Nutrition.* 2018; 120:49-56.
35. Marshall Chalmers JN, Shinton NK. Comparison of hydroxocobalamin and cyanocobalamin in the treatment of pernicious anaemia. *Lancet.* 1965;286(7426):1305–8.
36. Sanz-Cuesta T, Escortell-Mayor E, Cura-Gonzalez I, Martin-Fernandez J, Riesgo-Fuertes R, Garrido-Elustondo S et al. Oral versus intramuscular administration of vitamin B12 for vitamin B12 deficiency in primary care: a pragmatic, randomized, non-inferiority clinical trial (OB12). 2020;10: e033687.
37. Silverstein WK, Lin Y, Dharma C, Croxford R, Earle CC, Cheung MC. Prevalence of Inappropriateness of Parenteral Vitamin B<sub>12</sub> Administration in Ontario, Canada. *JAMA Intern Med.* 2019;179(10):1434–1436.
38. Nyholm E, Turpin P, Swain D, Cunningham B, Daly S, Nightingale P, et al. Oral vitamin B12 can change our practice. *Postgrad Med J.* 2003;79(930):218–20.
39. Kwong JC, Carr D, Dhalla IA, Tom-Kun D, Upshur RE. Oral vitamin B12 therapy in the primary care setting: a qualitative and quantitative study of patient perspectives. *BMC Fam Pract.* 2005;6(1):8.